Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 463

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 2
Chunk 463
---
 for our product candidates and any future product candidates and, if any product candidate receives marketing approval, commercialization activities. These increases will likely include increased costs related to the hiring of additional personnel and fees paid to outside consultants, among other expenses. We also anticipate increased expenses related to audit, accounting, legal and regulatory services associated with public company reporting and compliance, director and officer insurance premiums, investor and public relations costs and other administrative and professional services associated with operating as a public company.

Interest Income

Interest income consists primarily of interest earned and the amortization of discount or premiums on our cash equivalents and investments in marketable securities. 

Other Income

Other income consists of sublease income through our subleasing agreement which is further discussed within Note 7, “Leases,” in our audited consolidated annual financial statements in the Annual Report.

19

Results of Operations

Comparison of the Three Months Ended September 30, 2025 and 2024

The following table summarizes our results of operations (in thousands):

Three Months Ended September 30,Change20252024Operating expenses:Research and development$16,044 $24,582 $(8,538)General and administrative7,761 3,402 4,359 Total operating expenses23,805 27,984 (4,179)Loss from operations(23,805)(27,984)4,179 Other income:Interest income3,456 2,353 1,103 Other income71 190 (119)Total other income:3,527 2,543 984 Net loss$(20,278)$(25,441)$5,163 

 Research and Development Expenses

The following table summarizes our research and development expenses (in thousands):

Three Months Ended September 30,Change20252024Direct research and development expenses by program:NBD1 and combination development programs(1)$8,609 $5,815 $2,794 Complementary modulator programs1,532 1,253 279 Unallocated research and development expenses:IPR&D acquisition related costs— 13,639 (13,639)Personnel-related (including stock-based compensation)3,886 2,339 1,547 Other R&D related costs1,377 869 508 Facility, lab and depreciation640 667 (27)Total research and development expenses$16,044 $24,582 $(8,538)

(1)NBD1 and